保健医学研究与实践2025，Vol.22Issue(12)：54-59,6.DOI:10.11986/j.issn.1673-873X.2025.12.08
阿替普酶联合瑞舒伐他汀治疗急性脑梗死的临床效果观察
Clinical observation of alteplase combined with rosuvastatin in the treatment of acute cerebral infarction
摘要
Abstract
Objective To investigate the efficacy of alteplase combined with rosuvastatin in patients with acute cerebral infarc-tion(ACI)and its effects on serum B-type natriuretic peptide(BNP),D-dimer(D-D),and high-sensitivity C-reactive pro-tein(hs-CRP).Methods One hundred ACI patients admitted to the Affiliated Chuzhou Hospital of Anhui Medical Univer-sity from June 2022 to December 2024 were enrolled.Patients were assigned to a control group and an observation group u-sing a random number table,with 50 cases each.The control group received alteplase;the observation group received rosuv-astatin calcium in addition to the control regimen.Clinical efficacy was compared between the two groups.National Institu-tes of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)scores,and serum BNP,D-D,hs-CRP,and hemato-crit(HCT)were measured before treatment and at day 14 of treatment.Adverse events during treatment were recorded and compared.Results The overall response rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in NIHSS or mRS scores between the two groups(P>0.05).After treatment,NIHSS and mRS scores in both groups were decreased,and the observation group scores were lower than those of the control group;the differences were statistically significant(P<0.05).Before treatment,BNP,D-D,hs-CRP,or HCT levels did not differ significantly between groups(P>0.05).After treatment,BNP,D-D,hs-CRP,HCT levels in both groups showed reductions,and levels in the observation group were lower than those in the control group;the differences were statistically significant(P<0.05).The incidence of ad-verse reactions did not differ significantly between the two groups(P>0.05).Conclusion Combined treatment with alte-plase and rosuvastatin for ACI yields favorable clinical efficacy,can improve neurological function,reduce serum BNP,D-D,hs-CRP,and HCT levels,and demonstrate good clinical safety.关键词
急性脑梗死/阿替普酶/瑞舒伐他汀/疗效/神经功能/脑钠肽/D-二聚体/超敏C反应蛋白Key words
Acute cerebral infarction/Alteplase/Rosuvastatin/Efficacy/Neurological function/B-type natriuretic peptide/D-dimer/High-sensitivity C-reactive protein分类
医药卫生引用本文复制引用
孙京华,张成刚,郝井兰,戴文,周圆,王国珍,陈浪..阿替普酶联合瑞舒伐他汀治疗急性脑梗死的临床效果观察[J].保健医学研究与实践,2025,22(12):54-59,6.基金项目
2022年安徽省重点研究与开发计划项目(2022e07020058) （2022e07020058）
2022年度安徽省转化医学研究院科研基金项目(2022zhyx-B04). （2022zhyx-B04）
